Anemia and the need for high doses of anemia drugs linked with increased risk of premature death
Highlights• Control of anemia in children on dialysis varies by region around the globe. • Poor response to anemia medications is linked with inflammation, fluid retention, and hyperparathyroidism. • Anemia and the need for high doses of anemia medications are linked with an increased risk of dying prematurely.
Anemia is a common complication of kidney disease.
Newswise — Washington, DC (March 7, 2013) — Children on dialysis who have anemia and who require high doses of drugs to treat it have an increased risk of dying prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings provide new insights that may help improve the health of children with kidney failure.
Many patients on dialysis develop anemia, which can be treated with erythropoesis stimulating agents (ESAs) to boost hemoglobin, the component of blood that transports oxygen throughout the body. Using these medications presents considerable challenges, though: patients respond differently to the drugs, and using them too aggressively increases the risk of heart-related problems and premature death. Proper anemia control in children on dialysis is even less clear than in adults.
Franz Schaefer, MD (University of Heidelberg) and his colleagues conducted a five-year study to examine anemia control in children undergoing chronic peritoneal dialysis, hoping to identify factors that interfere with anemia management and to assess whether there are upper and lower hemoglobin levels that may compromise patient survival. The study included nearly 1,400 children and adolescents from 81 pediatric dialysis centers in 30 countries around the globe.
“Given the low incidence of pediatric end-stage renal disease in children—only 1% to 2% of all dialysis patients are children—this study is remarkable as it overcame the patient size limitations that notoriously hamper clinical research in this area,” said Dr. Schaefer.
Among the major findings: • In 25% of patients, hemoglobin was lower than clinical guidelines recommend. European and North American centers generally achieved higher hemoglobin ranges than centers in Asia, Turkey, and some Latin American countries.• ESAs were prescribed to 92% of patients, and neither the type of ESA nor the dosing interval appeared to affect efficacy. • Poor response to ESAs was linked with inflammation, fluid retention, and hyperparathyroidism (a disorder of the parathyroid gland).• Low hemoglobin and the need for high ESA doses indicated an increased risk of dying while on dialysis.
“We gained valuable insights regarding the clinical variation of anemia control, ESA dose-response relationships, the factors associated with low and high hemoglobin, and the relationship of hemoglobin control with the survival of children on dialysis,” said Dr. Schaefer. “The relevance of the study findings clearly goes beyond the pediatric setting; whereas most studies in adults have focused on anemia management in hemodialysis patients, this study included the largest peritoneal dialysis population ever assessed in this respect,” he added.
Study co-authors include Dagmara Borzych-Duzalka, MD, Yelda Bilginer, MD, Il Soo Ha, MD, Mustafa Bak, MD, Lesley Rees, MD, Francisco Cano, MD, Reyner Loza Munarriz, MD, Annabelle Chua, MD, Silvia Pesle, MD, Sevinc Emre, MD, Agnieszka Urzykowska, MD, Lily Quiroz, MD, Javier Darío Ruscasso, MD, Colin White, MD, Lars Pape, MD, Virginia Ramela, MD, Nikoleta Printza, MD, Andrea Vogel, MD, Dafina Kuzmanovska, MD, Eva Simkova, MD, Dirk E. Müller-Wiefel, MD, Anja Sander, MD, and Bradley Warady, MD, for the International Pediatric Peritoneal Dialysis Network (IPPN) Registry.
Disclosures: The authors reported no financial disclosures.
The article, entitled “Management of Anemia in Children Receiving Chronic Peritoneal Dialysis,” will appear online at http://jasn.asnjournals.org/ on March 7, 2013, doi: 10.1681/ASN.2012050433.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #